Publication:

How to unleash mitochondrial apoptotic blockades to kill cancers?

Thumbnail Image

Open/View Files

5237704.pdf (811.77 KB)

Date

2017

Authors

Published Version

10.1016/j.apsb.2016.08.005

Journal Title

Journal ISSN

Volume Title

Publisher

Elsevier
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Deng, Jing. 2017. “How to unleash mitochondrial apoptotic blockades to kill cancers?” Acta Pharmaceutica Sinica. B 7 (1): 18-26. doi:10.1016/j.apsb.2016.08.005. http://dx.doi.org/10.1016/j.apsb.2016.08.005.

Abstract

Apoptosis, especially the intrinsic mitochondrial cell death pathway, is regulated by the BCL-2 family of proteins. Defects in apoptotic machinery are one of the main mechanisms that cells employ to evade cell death and become cancerous. Targeting the apoptotic defects, either by direct inhibition of BCL-2 family proteins or through modulation of regulatory pathways, can restore cell sensitivity to cell death. This review will focus on the aspects of BCL-2 family proteins, their interactions with kinase pathways, and how novel targeted agents can help overcome the apoptotic blockades. Furthermore, functional assays, such as BH3 profiling, may help in predicting responses to chemotherapies and aid in the selection of combination therapies by determining the mitochondrial threshold for initiating cell death.

Description

Other Available Sources

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237704/pdf/

Research Data

Keywords

ASH, American Society of Hematology, ATAP, amphipathic tail-anchoring peptide, BAD, BCL-2-associated death promoter protein, BAK, BCL-2 homologous antagonist killer, BAX, BCL-2-associated X protein, BCL-2, B-cell lymphoma 2, BCL-w (BCL2L2), BCL-2-like protein 2, BCL-xL, B-cell lymphoma X long, BFL-1 (BCL2A1), BCL-2-related protein A1, BCR, B-cell receptor, BH3, BCL-2 homology 3, BID, BH3 interacting domain death agonist, BIK, BCL-2-interacting killer, BIM, BCL-2-interacting mediator of cell death, BOK, BCL-2 related ovarian killer, BTK, Bruton׳s tyrosine kinase, CDK, cyclin-dependent kinase, CLL, chronic lymphocytic leukemia, CHOP, cyclophosphamide, hydroxydaunorubicin, oncovin-vincristine and prednisone, CML, chronic myelogenous leukemia, CR, complete response;EGFR, epidermal growth factor receptor, ER, endoplasmic reticulum, ERK, extracellular signal-regulated kinase, FDA, U. S. Food and Drug Administration, GSK-3, glycogen synthase kinase-3, ITK, interleukin-2-inducible T-cell kinase, MCL, myeloid cell leukemia, MOMP, mitochondrial outer membrane permeabilization, NHL, non-Hodgkin lymphoma, NIH, National Institutes of Health, NSCLC, non-small cell lung cancer, PI3K, phosphatidylinositol-3-kinase, PUMA, p53 up-regulated modulator of apoptosis, SLL, small lymphocytic lymphoma, T-ALL, T-acute lymphocytic leukemia, Apoptosis, BCL-2 family, Mitochondrial priming, BH3 profiling, Targeted therapy, Combination therapy

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

URI

http://nrs.harvard.edu/urn-3:HUL.InstRepos:30370920

Collections

HMS Scholarly Articles

Endorsement

Review

Supplemented By

Related Stories